Over the past nine years, patients with spinal muscular atrophy have seen the number of FDA-approved treatment options for ...

Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is ...

Spinal muscular atrophy (SMA) therapy Spinraza has been a key earner for Biogen in recent years, but with sales now heading into reverse, the company is looking to extend its franchise.

Biogen Inc. (NASDAQ:BIIB) shares tumbled to a 52-week low of $139.7, reflecting a stark downturn in the biotechnology firm's market performance. With a market capitalization of $20.38 billion and a ...

The FDA on Wednesday approved the industry’s first-ever tablet treatment for spinal muscular atrophy— Roche ’s SMN2 splicing ...

Cost-effectiveness body NICE has rejected Biogen’s Spinraza (nusinersen) therapy for the rare genetic muscle wasting disease spinal muscular atrophy (SMA) because of its high cost – but is in ...

Biogen's officials expressed optimism about the potential benefits this regimen could offer to SMA patients and their families. The DEVOTE study, which evaluated the higher dose regimen's safety ...

The Muscular Dystrophy Association celebrates this new more accessible treatment option for people living with SMA. MDA - New ...

Biogen BIIB reported fourth-quarter 2024 adjusted earnings per share (EPS) of $3.44, which beat the Zacks Consensus Estimate ...

Biotech giant Biogen Inc (NASDAQ:BIIB) is scheduled to report fourth-quarter earnings on 12 February. The Wall Street ...

Biogen reported fourth-quarter 2024 earnings that surpassed analysts' expectations, driven by strong sales of new product ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.